<?xml version="1.0" encoding="UTF-8"?>
<p>Exploring and understanding the immunogenicity of COVID-19 is essential for developing the most effective treatment regimens and vaccine. However, evidence on immunogenicity of COVID-19 is limited. Study on B-cell and T-cells epitopes revealed that SARS-CoV and the virus causing COVID-19 had identical proteins (
 <xref rid="B32" ref-type="bibr">32</xref>). A few clinical trials have evaluated the efficacy of new vaccines in MERS-CoV and SARS-CoV. Results of these studies in Phase-1 showed some degree of efficacy and one of these studies has been certified to begin Phase-2 (
 <xref rid="B33" ref-type="bibr">33</xref>,
 <xref rid="B34" ref-type="bibr">34</xref>). 
</p>
